Reading ENOV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ENOV free→Reading ENOV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ENOV free→NYSEHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been steady, but risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 74% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. Key factors to watch include guidance changes and sector trends, particularly the performance of major healthcare companies. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $21.57. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $21 ENOV trades at 6× p/e, below its 23× p/e peer median. Our $80 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 74% below a flat-multiple fair value, below our forecast of about 7%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted -0.21x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the US dollar.
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.86 → $0.85 (-0.6% / 30d). 1 raised, 8 cut, 12 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 92% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$201.
How much price usually moves either way.
On a bad day, this stock has moved -$583.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,160.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
The signal changed to "mild favorable." This indicates a more positive outlook. Risk remains elevated. The sector backdrop is a headwind, which could affect performance.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If Enovis meets or beats this growth rate, it shows they are on track. This also shows strong sales and new ideas.
Confirms:Q2 revenue growth of 4% or more compared to Q2 2025.
Disproves:Q2 revenue growth falls below 4% YoY.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ENOV yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Approval of an Amendment to the Enovis Corporation 2020 Omnibus Incentive Plan At the Annual Meeting of Stockholders of Enovis Corporation (the “Company”) held on May 19, 2026 (the “Annual Meeting”), the Company’s stockholders voted on and approved an amendment to the Company’s 2020 Omnibus Incentive Plan (the “2020 Plan Amendment”). The 2020 Plan…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ENOV Enovis | Typical Show detailsSector percentile: 67 of 100 | inexpensive | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Typical Show detailsSector percentile: 54 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain the revenue guidance for 2026 between $2.31 billion and $2.37 billion.
Continue to target adjusted EBITDA within the range of $425 million to $435 million for 2026.
Emphasize commercial execution and innovation to drive growth and competitive positioning.
Focus on improving operating income through cost management and revenue growth.
Drive revenue growth through strategic market expansion and product innovation.
Why it matters: Staying in this range shows Enovis is keeping its profit goals, even with challenges.
Confirms:Adjusted EBITDA reported in Q2 falls within the $425-435 million range.
Disproves:Adjusted EBITDA in Q2 is less than $425 million.
Why it matters: Lower growth would signal trouble in meeting the full-year revenue guidance of $2.31-2.37 billion.
Confirms:Q2 organic revenue growth was less than 4%.
Disproves:Q2 organic revenue growth reported at 4% or higher.
Why it matters: Higher gross profit means better efficiency. This is key for long-term success.
Confirms:Q2 gross profit rises above $370M, indicating better cost control.
Disproves:Q2 gross profit drops below $360M. This shows ongoing operational issues.
Why it matters: Strong growth in the Reconstructive segment shows good product launches and high market demand.
Confirms:Reconstructive segment net sales grew more than 10% from Q2 2025.
Disproves:Reconstructive segment net sales growth is below 10% YoY.
Why it matters: Better operating income means Enovis is managing costs and running efficiently. These are key goals.
Confirms:Operating income in Q2 shows a positive change compared to Q1 2026.
Disproves:Operating income in Q2 declines further from Q1 2026.
Results of Operations and Financial Condition. On May 7, 2026, the Company issued a press release reporting financial results for the first quarter ended April 3, 2026. A copy of the Company's press release is attached to this report as Exhibit 99.1 and is incorporated into
Results of Operations and Financial Condition. On February 26, 2026, the Company issued a press release reporting financial results for the year ended ended December 31, 2025. A copy of the Company's press release is attached to this report as Exhibit 99.1 and is incorporated into